Top

The Patient - Patient-Centered Outcomes Research

Published in:

01-08-2017 | Commentary

Giving Patients a Meaningful Voice in United States Regulatory Decision Making: The Role for Health Preference Research

Authors: F. Reed Johnson, Kathleen Beusterien, Semra Özdemir, Leslie Wilson

Published in: The Patient - Patient-Centered Outcomes Research | Issue 4/2017

Excerpt

Weighing the benefits and risks of new health technologies requires assessing the available scientific evidence but also making societal value judgments about the relative importance of those benefits and risks [1]. Such judgments traditionally have been delegated to physicians. Increasingly, however, patients are claiming a greater role in such assessments. This paper discusses the increasing concern of the US FDA in strengthening patient engagement by conducting health preference research (HPR) on patients’ risk tolerance. …

Hammad TA, Neyarapally GA, Iyasu S, Staffa JA, Del Pan G. The future of population-based postmarket drug risk assessment: a regulator’s perspective. Clin Pharmacol Ther. 2013;94(3):349–58.CrossRef

Woodcock J. CDER 2016 Priorities. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM477299.pdf. Accessed 18 Mar 2016.

Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013–2015. Fed Regist. 2013;78:21613–4.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). June 2015. Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment: Guidance for Industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM450229.pdf. Accessed 18 Mar 2016.

US Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making. Draft PDUFA V implementation plan—February 2013. Fiscal years 2013–2017. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf. Accessed 18 Mar 2016.

Kesselheim AS, Avorn J. Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA. 2016;316(22):2357–8. doi:10.1001/jama.2016.16437.CrossRefPubMed

US Department of Health and Human Services, FDA, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. Guidance for Industry and Food and Drug Administration Staff: Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. March 28, 2012. Available at https://duke.box.com/s/rrllbrq57b8imsdb9uv1ys5qdfudm94p. Accessed 1 June 2017.

US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research. Patient Preference Information—Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 24 August 2016. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf. Accessed 16 Jan 2017.

Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, Hauber AB, Irony T. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984–93.CrossRef

10.

Summary of Safety and Effectiveness Data (SSED). MAESTRO Rechargeable System. 14 Jan 2015. PMA Number P130019. Pages 1–44. http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130019b.pdf. Accessed 18 Mar 2016.

11.

Frederiks ER, Stenner K, Hobman EV. Household energy use: applying behavioural economics to understand consumer decision-making and behaviour. Renew Sustain Energy Rev. 2015;41:1385–94.CrossRef

12.

Cialdini RB, Trost MR. Social influence: social norms, conformity and compliance. In: Gilbert DT, Fiske ST, Lindzey G, editors. The handbook of social psychology. 4th ed. New York: McGraw-Hill; 1998. p. 151–92.

13.

Bridges JFP, Hauber AB, Marshal D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:402–13.CrossRef

Title: Giving Patients a Meaningful Voice in United States Regulatory Decision Making: The Role for Health Preference Research
Authors: F. Reed Johnson
Kathleen Beusterien
Semra Özdemir
Leslie Wilson
Publication date: 01-08-2017
Publisher: Springer International Publishing
Published in: The Patient - Patient-Centered Outcomes Research / Issue 4/2017
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI: https://doi.org/10.1007/s40271-017-0250-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2017

Comment on: “Moving from Patient Advocacy to Partnership: A Long and Bumpy Road”

Author’s Reply to Braillon: “Moving from Patient Advocacy to Partnership: A Long and Bumpy Road”

Health Preference Research: An Overview

Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus

Development of a Report Card for Identifying Local Sublingual Immunotherapy Events in Clinical Trials

Art and Science of Instrument Development for Stated-Preference Methods

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials